[{"AccountsPayableCurrent_0_Q3_USD":27872000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q3_USD":1294955000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q3_USD":1294050000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q3_USD":300000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q3_USD":1205000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q3_USD":40228000.0,"DepreciationAmortizationAndAccretionNet_3_Q3_USD":24386000.0,"OtherLiabilitiesNoncurrent_0_Q3_USD":16341000.0,"AllocatedShareBasedCompensationExpense_3_Q3_USD":105597000.0,"AllocatedShareBasedCompensationExpense_1_Q3_USD":37264000.0,"PaymentsForProceedsFromOtherInvestingActivities_3_Q3_USD":300000.0,"IncreaseDecreaseInContractWithCustomerLiability_3_Q3_USD":-15924000.0,"ProceedsFromSaleAndMaturityOfMarketableSecurities_3_Q3_USD":1190714000.0,"RestrictedCashCurrent_0_Q3_USD":5000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q3_USD":1279955000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_3_Q3_USD":768000.0,"AccountsReceivableNet_0_Q3_USD":18331000.0,"RepaymentsOfLongTermDebt_3_Q3_USD":0.0,"InvestmentIncomeInterest_3_Q3_USD":10717000.0,"InvestmentIncomeInterest_1_Q3_USD":2072000.0,"OtherComprehensiveIncomeLossNetOfTax_3_Q3_USD":-675000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q3_USD":-3981000.0,"ComprehensiveIncomeNetOfTax_3_Q3_USD":-615416000.0,"ComprehensiveIncomeNetOfTax_1_Q3_USD":-257272000.0,"AdditionalPaidInCapitalCommonStock_0_Q3_USD":5592884000.0,"OtherAssetsNoncurrent_0_Q3_USD":37932000.0,"NonoperatingIncomeExpense_3_Q3_USD":22215000.0,"NonoperatingIncomeExpense_1_Q3_USD":-27253000.0,"CostOfGoodsAndServicesSold_3_Q3_USD":55028000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q3_USD":-1481000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q3_USD":15000000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q3_USD":499156000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_3_Q3_USD":-50472000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_3_Q3_USD":329291000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q3_USD":125853000.0,"RestrictedInvestmentsNoncurrent_0_Q3_USD":24725000.0,"RestrictedCashNoncurrent_0_Q3_USD":2447000.0,"ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_3_Q3_USD":-983000.0,"ProceedsFromSaleOfRestrictedInvestments_3_Q3_USD":0.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3_Q3_USD":181459000.0,"ProceedsFromDerivativeInstrumentFinancingActivities_3_Q3_USD":4200000.0,"PaymentsToAcquireRestrictedInvestments_3_Q3_USD":9900000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_3_Q3_USD":1469451000.0,"PaymentsForProceedsFromTenantAllowance_3_Q3_USD":-2690000.0,"OtherOperatingActivitiesCashFlowStatement_3_Q3_USD":1628000.0,"OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_3_Q3_USD":-222000.0,"OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeReclassificationAdjustmentsNetOfTax_1_Q3_USD":-76000.0,"OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_3_Q3_USD":-1658000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_3_Q3_USD":-1665000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_1_Q3_USD":-2576000.0,"OperatingLeaseRightOfUseAsset_0_Q3_USD":245234000.0,"OperatingLeasePayments_3_Q3_USD":31272000.0,"OperatingLeaseLiabilityNoncurrent_0_Q3_USD":297262000.0,"OperatingLeaseLiabilityCurrent_0_Q3_USD":32192000.0,"EquitySecuritiesFvNiGainLoss_3_Q3_USD":66626000.0,"EquitySecuritiesFvNi_0_Q3_USD":57217000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_Q3_USD":1946000.0,"ContractWithCustomerLiabilityRevenueRecognized_3_Q3_USD":50716000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q3_USD":19212000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q3_USD":265708000.0,"ContractWithCustomerLiabilityCurrent_0_Q3_USD":114601000.0,"ContractWithCustomerLiability_0_Q3_USD":145692000.0,"CostOfGoodsAndServicesSold_1_Q3_USD":21797000.0,"RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_3_Q3_USD":34363000.0,"CapitalExpendituresIncurredButNotYetPaid_3_Q3_USD":7048000.0,"OtherNonoperatingIncomeExpense_3_Q3_USD":67477000.0,"NetIncomeLoss_3_Q3_USD":-614741000.0,"NetIncomeLoss_1_Q3_USD":-253291000.0,"NetCashProvidedByUsedInOperatingActivities_3_Q3_USD":-491817000.0,"NetCashProvidedByUsedInInvestingActivities_3_Q3_USD":-337630000.0,"NetCashProvidedByUsedInFinancingActivities_3_Q3_USD":777029000.0,"LiabilitiesCurrent_0_Q3_USD":480241000.0,"LiabilitiesAndStockholdersEquity_0_Q3_USD":3307283000.0,"Liabilities_0_Q3_USD":2092260000.0,"InventoryNet_0_Q3_USD":66942000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_3_Q3_USD":-3765000.0,"IncreaseDecreaseInAccountsReceivable_3_Q3_USD":35070000.0,"IncomeTaxExpenseBenefit_3_Q3_USD":2740000.0,"IncomeTaxExpenseBenefit_1_Q3_USD":839000.0,"PaymentsToAcquirePropertyPlantAndEquipment_3_Q3_USD":48693000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3_Q3_USD":-612001000.0,"EarningsPerShareBasicAndDiluted_3_Q3_USD":-5.37,"EarningsPerShareBasicAndDiluted_1_Q3_USD":-2.18,"CostsAndExpenses_3_Q3_USD":963507000.0,"CostsAndExpenses_1_Q3_USD":351052000.0,"CommonStockValue_0_Q3_USD":1161000.0,"CommonStockSharesOutstanding_0_Q3_shares":116143000.0,"CommonStockSharesIssued_0_Q3_shares":116143000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q3_USD":496704000.0,"AssetsCurrent_0_Q3_USD":2554702000.0,"Assets_0_Q3_USD":3307283000.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3_Q3_shares":13001000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q3_USD":-37193000.0,"AccountsReceivableNetCurrent_0_Q3_USD":79118000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q3_USD":-252452000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q3_USD":74766000.0,"ProceedsFromIssuanceOfCommonStock_3_Q3_USD":0.0,"PropertyPlantAndEquipmentNet_0_Q3_USD":444690000.0,"OtherNonoperatingIncomeExpense_1_Q3_USD":-594000.0,"InventoryWorkInProcess_0_Q3_USD":22425000.0,"InventoryRawMaterials_0_Q3_USD":54354000.0,"InventoryFinishedGoods_0_Q3_USD":7261000.0,"IncreaseDecreaseInInventories_3_Q3_USD":26962000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3_Q3_USD":75564000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q3_USD":32212000.0,"ShareBasedCompensation_3_Q3_USD":105597000.0,"SellingGeneralAndAdministrativeExpense_3_Q3_USD":422129000.0,"SellingGeneralAndAdministrativeExpense_1_Q3_USD":167472000.0,"ResearchAndDevelopmentExpense_3_Q3_USD":486350000.0,"ResearchAndDevelopmentExpense_1_Q3_USD":161783000.0,"PreferredStockValue_0_Q3_USD":0.0,"PreferredStockSharesOutstanding_0_Q3_shares":0.0,"PreferredStockSharesIssued_0_Q3_shares":0.0,"PreferredStockSharesAuthorized_0_Q3_shares":5000000.0,"PreferredStockParOrStatedValuePerShare_0_Q3_USD":0.01,"OperatingIncomeLoss_3_Q3_USD":-634216000.0,"OperatingIncomeLoss_1_Q3_USD":-225199000.0,"InterestExpense_3_Q3_USD":55979000.0,"InterestExpense_1_Q3_USD":28731000.0,"CommonStockSharesAuthorized_0_Q3_shares":250000000.0,"CommonStockParOrStatedValuePerShare_0_Q3_USD":0.01,"CommitmentsAndContingencies_0_Q3_USD":null,"AccruedLiabilitiesCurrent_0_Q3_USD":295260000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_3_Q3_shares":114554000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q3_shares":115986000.0,"StockholdersEquity_0_Q3_USD":1215023000.0,"RetainedEarningsAccumulatedDeficit_0_Q3_USD":-4341829000.0,"ProceedsFromIssuanceOfPrivatePlacement_3_Q3_USD":99498000.0,"StockIssuedDuringPeriodValueShareBasedCompensationGross_1_Q3_USD":129000.0,"Ticker":"ALNY","CIK":"1178670","name":"ALNYLAM PHARMACEUTICALS, INC.","OfficialName":"Alnylam Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20200930","fy":"2020.0","fp":"Q3","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"19459816074.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20201105"}]